A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of pomalidomide therapy in myelofibrosis

(2011) Kebede H. Begna et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

(2010) Alejandra Martínez-Trillos et al.   ANNALS OF HEMATOLOGY

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*

(2010) Eva Löfvenberg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD